Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

94.29 +0.14 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRO, EA, MRUS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Unusual volume stocks are being observed in Thursday's session.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA and MRUS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal
Via Stocktwits
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race
Via Stocktwits
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
From Kahn Swick & Foti, LLC
Via Business Wire
This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Wall Street Lights Up as Cannabis Stocks Blaze Higher, Biotech Melts Down
U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by... 
Via Chartmill
Topics Cannabis
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
Let's take a look at the stocks that are in motion in today's session.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.... 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
From Brodsky & Smith LLC
Via GlobeNewswire
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Tilray Brands, SNDL, Innoviz Technologies, Pony AI And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Monday. Shares of Tilray Brands, Inc. (NASDAQ: TLRY) rose sharply during Monday's session. 
Via Benzinga
Topics Artificial Intelligence Stocks
There are notable gap-ups and gap-downs in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. 
Via Benzinga
Expert Outlook: Merus Through The Eyes Of 4 Analysts
In the preceding three months, 4 analysts have released ratings for Merus (NASDAQ: MRUS), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent... 
Via Benzinga
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
The takeover candidate is working on a bispecific antibody, capable of simultaneously blocking two drivers of cancer. 
Via Investor's Business Daily
Topics Government
Wondering what's happening in today's pre-market session?
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million. 
Via Benzinga
MRUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Merus N.V. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
From Genmab A/S
Via Business Wire
Merus to Present at the 2025 Wells Fargo Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Merus N.V.
Via GlobeNewswire
MERUS NV (NASDAQ:MRUS) - A Technical Breakout Candidate Worth Watching
MERUS NV (NASDAQ:MRUS) shows strong technicals with a 7/10 rating and a high-quality 9/10 setup, suggesting a potential breakout above $56.23. Support at $52.32-53.52 provides a clear risk level. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.